/
Amylyx Pharmaceuticals, Inc. (also referred to as Amylyx, we, our or us) is a clinical-stage pharmaceutical company with a mission to develop and advance novel therapies for communities with high unmet medical needs. We have preclinical and clinical development programs underway in endocrine conditions and neurodegenerative diseases.
Revenue declined 100.0% YoY. The question is whether this is cyclical or a structural shift.
Negative free cash flow of -$123M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$0.00
▼ -100.0% YoY
Net Income (TTM)
-$150M
▲ +52.0% YoY
Op. Margin
—
ROIC
-45.68%
▲ +31.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$120M
▲ +26.4% YoY
Op. Cash Flow (TTM)
-$120M
▲ +26.4% YoY
Net Debt
-$274M
Net Cash Position
Cash & Equiv.
$280M
Continue Research